RobertSNegrinMD
Hematology • Stanford, CAProfessor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center
Dr. Negrin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-724-6182
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Neonatal-Perinatal Medicine, 1988 - 1989- Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1987 - 1988
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1984 - 1987
Harvard Medical SchoolClass of 1984
Certifications & Licensure
CA State Medical License 1985 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation Start of enrollment: 2004 Jun 01
- Bone Marrow Grafting for Leukemia and Lymphoma Start of enrollment: 1988 Mar 01
- Transplantation for Patients With Chronic Lymphocytic Leukemia Start of enrollment: 1996 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsA phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.Hrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, Nikeshan Jeyakumar, Mark Hamilton
Blood. 2024-10-17 - Management of post-autologous transplant relapse in patients with T-cell lymphomas.Olivier Veilleux, Francisco Socola, Sally Arai, Matthew J Frank, Laura Johnston
American Journal of Hematology. 2024-08-01 - Extracellular release of damaged mitochondria induced by prehematopoietic stem cell transplant conditioning exacerbates GVHD.Vijith Vijayan, Hao Yan, Juliane K Lohmeyer, Kaylin A Prentiss, Rachna V Patil
Blood Advances. 2024-07-23
Abstracts/Posters
- Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-PrimingRobert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel AgentsRobert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Activation of Regulatory T Cells with IL-2 and TNF-_ to Promote Homing to the Gut and to Improve Acute GvHD PreventionRobert S. Negrin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- How to Peer Review a Scientific Paper61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Volunteering Your Skills Overseas60th American Society of Hematology Annual Meeting - 11/30/2018
Other
- Preparative regimens for hematopoietic cell transplantationNegrin RS
http://www.uptodate.com/contents/preparative-regimens-for-hematopoietic-cell-transplantation
UpToDate, Wolters Kluwer Health - 2013-02-25 - Oral toxicity associated with chemotherapyNegrin RS, Bedard J, Toljanic JA
http://www.uptodate.com/contents/oral-toxicity-associated-with-chemotherapy
UpToDate, Wolters Kluwer Health - 2012-12-21 - Busulfan-induced pulmonary injuryNegrin RS, Russi EW
http://www.uptodate.com/contents/busulfan-induced-pulmonary-injury
UpToDate, Wolters Kluwer Health - 2012-08-13 - Join now to see all
Authored Content
- Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023
Press Mentions
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021- Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
ASH Launches Digital, Open-Access JournalNovember 29th, 2016- Join now to see all
Grant Support
- Role Of Regulatory T Cells In GVHD, Gvt, And Tolerance InductionNational Heart, Lung, And Blood Institute2010–2011
- HematopoeticNational Cancer Institute2010–2011
- NK Cells In GVHD And GVTNational Cancer Institute2008–2011
- Control Of GVHD With Retained GVTNational Cancer Institute2007–2011
- Allografting For LukemiaNational Cancer Institute2007–2011
- Training Program In Hematopoietic Cell TransplantationNational Heart, Lung, And Blood Institute2001–2011
- Bone Marrow Grafting For Leukemia And LymphomaNational Cancer Institute2000–2011
- Regulatory T Cells In Allogeneic TransplantationNational Heart, Lung, And Blood Institute2009–2010
- Prog 8- Hematopoietic Cell Transplantation AndNational Cancer Institute2007–2009
- Regulatory T Cells Which Allow GVT Without GVHDNational Heart, Lung, And Blood Institute2004–2008
- Administration And Research CoordinationNational Cancer Institute2007
- Visualizing Tumors And Mechanisms Of Therapy In VivoNational Cancer Institute1999–2007
- BMT Clinical Trial Network At StanfordNational Heart, Lung, And Blood Institute2002–2003
- Allografting For LeukemiaNational Cancer Institute2002
- Cytokine Induced Killer Cells After Autologous/Allogenic Marrow TransplantationNational Cancer Institute1997–2002
- BMT Clinical Trial Netwrok At StanfordNational Heart, Lung, And Blood Institute2001
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
